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Abstract
The persistence of a reservoir of latently infected CD4 T cells remains one of the major
obstacles to cure HIV. Numerous strategies are being explored to eliminate this reservoir.
To translate these efforts into clinical trials, there is a strong need for validated biomarkers
that can monitor the reservoir over time in vivo. A comprehensive study was designed to
evaluate and compare potential HIV-1 reservoir biomarkers. A cohort of 25 patients, treated
with suppressive antiretroviral therapy was sampled at three time points, with median of 2.5
years (IQR: 2.4–2.6) between time point 1 and 2; and median of 31 days (IQR: 28–36)
between time point 2 and 3. Patients were median of 6 years (IQR: 3–12) on ART, and
plasma viral load (<50 copies/ml) was suppressed for median of 4 years (IQR: 2–8). Total
HIV-1 DNA, unspliced (us) and multiply spliced HIV-1 RNA, and 2LTR circles were quanti-
fied by digital PCR in peripheral blood, at 3 time points. At the second time point, a viral out-
growth assay (VOA) was performed, and integrated HIV-1 DNA and relative mRNA
expression levels of HIV-1 restriction factors were quantified. No significant change was
found for long- and short-term dynamics of all HIV-1 markers tested in peripheral blood.
Integrated HIV-1 DNA was associated with total HIV-1 DNA (p<0.001, R² = 0.85), us HIV-1
RNA (p = 0.029, R² = 0.40), and VOA (p = 0.041, R2 = 0.44). Replication-competent virus
was detected in 80% of patients by the VOA and it correlated with total HIV-1 DNA (p =
0.039, R² = 0.54). The mean quantification difference between Alu-PCR and VOA was 2.88
log10, and 2.23 log10 between total HIV-1 DNA and VOA. The levels of usHIV-1 RNA were
inversely correlated with mRNA levels of several HIV-1 restriction factors (TRIM5α,
SAMHD1, MX2, SLFN11, pSIP1). Our study reveals important correlations between the
viral outgrowth and total and integrated HIV-1 DNAmeasures, suggesting that the total pool
of HIV-1 DNAmay predict the size of the replication-competent virus in ART suppressed
patients.
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Author Summary
Current HIV-1 research aims to find a cure for HIV-1, either by pursuing viral eradication
or by attempting to attain an immune-mediated functional cure. For the purpose of inter-
preting the findings of these eradication strategies, a validated representative biomarker of
the replication-competent latent HIV-1 reservoir is urgently needed. In this study we have
evaluated several cell-associated HIV-1 persistence markers, and we have measured repli-
cation-competent reservoir using the viral outgrowth assay (VOA). The results show a
correlation between the pool of HIV-1 DNA and the replication-competent reservoir. Our
data show that the pool of HIV-1 DNA (total or integrated HIV-1 DNA) can predict the
amount of replication-competent latent HIV-1 in patients receiving treatment. Hence,
PCR based assays quantifying integrated and/or total HIV-1 DNA can play an important
role in future studies aiming at HIV-1 eradication.
Introduction
Current antiretroviral therapy (ART) successfully suppresses viral replication and reduces
HIV-1 transmission, but fails to completely eliminate HIV-1 [1]. Even after long-term ART, a
latent reservoir of HIV-1 DNA persists and remains fully competent to refuel viral rebound
when ART is stopped [2, 3]. An increasing number of strategies to target the latent HIV-1 res-
ervoir are being pursued and initial patient clinical trials have been performed [4]. However,
interpretation of clinical data is hampered due to the lack of validated biomarkers that can
monitor the size of the replication-competent reservoir.
Different markers to monitor changes in the size and composition of the viral reservoir are
being explored [5]. In this context, it is crucial to clearly define the characteristics of the reser-
voir that causes viral rebound upon treatment discontinuation. It is well known that only a
small fraction of integrated HIV-1 DNA is composed of intact HIV-1 DNA that is capable to
produce replication-competent virus. This small fraction of replication-competent virus is the
sole contributor to viral persistence and sole source of viral rebound after treatment discontin-
uation. Hence, an effective biomarker needs to correlate with the changes in the fraction of the
replication-competent reservoir and should not be biased by the levels of archival, dead-end
integrated proviruses [5].
The existence of the replication-competent viral reservoir was first observed by experiments
in which latent provirus was reactivated after stimulation of isolated patient CD4+ T cells
using the so-called viral outgrowth assay (VOA) [5, 6]. VOAs have now been designed to quan-
tify the replication-competent viral reservoir by reactivating multiple replicates at a limiting
dilution [6]. The VOA has long been considered as the gold standard for measuring the HIV-1
reservoir in patients. However, recent data indicate that the VOA underestimates the actual
viral reservoir, as consecutive reactivation of the initially negative cells often induces reactiva-
tion of virus which was not reactivated in the first round of stimulation [7]. This indicates that
the total number of intact viral sequences outnumbers the amount of virus that becomes reacti-
vated [7]. Therefore, it remains to be assessed whether the VOA outcome correlates with the
actual replication-competent viral reservoir in vivo. In addition, practical issues, such as time
to result, assay costs and the large amount of blood required may impede the implementation
of VOA assays in a clinical setting.
Alternative markers, based on quantitative PCR of total or integrated HIV-1 DNA have also
been explored [8]. These markers cannot discern dead-end integrated HIV-1 DNA from the
replication-competent reservoir. PCR-based markers overestimate the reservoir and this may
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obscure changes in the amount of replication-competent HIV-1 DNA [5]. Despite these draw-
backs, PCR based markers are the most commonly used tool in HIV reservoir research. These
assays combine a high sensitivity with a proficient accuracy. They are also cheap, easy to imple-
ment and can be performed for high throughput analysis. Interestingly, recent results indicate
that measuring total and integrated HIV-1 DNA may be clinically relevant. For instance, total
HIV-1 DNA was found to inversely correlate to the time to viral rebound in early treated
patients interrupting ART [9, 10]. In addition, markers for viral reservoir dynamics, such as
viral replication or mRNA transcription may also be promising tools to assess the effect of anti
HIV-1 latency interventions. Episomal 2LTR circles are formed as a transient by-product of
failed HIV-1 DNA integration, indicating recent production of new infective virus from the
reservoir [11]. Proviral transcription is quantified by measuring the amount of cell-associated
(CA) RNA [12, 13]. The levels of unspliced CA HIV-1 RNA are associated with virological fail-
ure in patients on treatment [11, 14].
A thorough validation of HIV-1 persistence markers in clinically relevant samples will be
needed to identify the optimal biomarker for HIV-1 reservoir research. This will require a com-
prehensive evaluation and comparison of candidate markers, and in the future, an assessment
of these markers in treatment interruption studies. Moreover, a critical comparison of the
quantitative agreement of the methods should be implemented, as a high correlation does not
automatically imply that there is good quantitative agreement [15]. To date, only limited stud-
ies have compared PCR-based assays with the VOA. An initial study by Eriksson et al., revealed
no correlation with HIV-1 DNA or 2LTR circles, but a significant association was observed
between integrated HIV-1 DNA and the VOA outcome [12]. In addition, a study of Buzon
et al., confirmed a significant correlation between VOA and HIV-1 DNA in CD4+ T-cells [16].
However, the levels of cell-associated HIV-1 RNA have not been compared to the VOA out-
come yet.
Here, we performed a comprehensive evaluation of viral reservoir markers quantified by
digital (dPCR) and real time PCR (qPCR) and by VOA. Subsequently, a Bland Altman analysis
was performed to evaluate the quantitative agreement between the methods. In addition, this
study aimed at evaluating both long- and short-term variation of PCR based reservoir markers
in order to guarantee that differences observed in intervention trials are genuine rather that
assay variations. We used 25 patient samples, selected from a previous study with the purpose
of having patients with varying levels of HIV-1 burden, representing the actual variation
observed in clinical samples. Moreover, the gene expression of several known HIV-1 restriction
and host factors was quantified to evaluate if these are correlated with any of the reservoir
markers.
Results
Characteristics of the study population
The majority of patients were males (19/25, 76%), with a median age of 48 years (IQR: 44–61).
Current CD4+ T count was median of 507 cells/μl (IQR: 420–642), and CD4+ T nadir count of
median 195 cells/μl (IQR: 118–260). The pre-ART plasma viral load was median of 5.0 log10
copies/ml (IQR: 4.7–5.6). All patients were receiving ART at the time of sampling, with median
of 6 years (IQR: 3–12) and a viral load suppression (<50 copies/ml) of median 4 years (IQR:
2–8). Patients had residual plasma HIV-1 RNA of median 4 copies/ml (IQR: 1–7) plasma,
which correlated well only with the baseline measurement for unspliced HIV- RNA (p = 0.028,
R2 = 0.40). About half of the patient cohort was infected with subtype B virus (52%), 20% with
non-B subtype and for the others (28%) the viral subtype was unknown.
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Long- and short-term dynamics of intracellular markers of HIV-1
persistence in blood
Measured markers of HIV-1 persistence in blood included total HIV-1 DNA, unspliced and
multiply spliced HIV-1 RNA, and 2-LTR circles in PBMCs of all patients at three different
time points. The time difference between baseline and second measurement was a median
(IQR) of 2.5 years (2.4–2.6), and the time difference between the second and third measure-
ment was a median (IQR) of 31 days (28–36) (Fig 1 workflow).
Unspliced HIV-1 RNA was detected in the majority of subjects at each time point (92%,
72%, 80%, respectively); with median log10 copies/10
6 CD4+ T cells of 1.3 (IQR: 0.9–1.7); 1.0
(IQR: 0.8–1.5) and 1.2 (IQR: 0.6–1.5) at the three time points, respectively. Multiply spliced
HIV-1 RNA was detected in 74%, 64%, 68% of patients at each time point, respectively; with
median log10 copies/10
6 CD4+ T cells of 0.6 (IQR: 0.4–0.9); median 0.5 (IQR: 0.3–0.7); and
median 0.5 (IQR: 0.3–0.5) at the three time points, respectively. Total HIV-1 DNA was
detected in all subjects at each time point; with median log10 copies/10
6 CD4+ T cells of 3.0
(IQR: 2.2–3.6), 3.4 (IQR: 2.6–3.7) and 3.1 (IQR: 2.4–3.6) at the three time points, respectively.
2LTR circles were detected in 52%, 56%, 76% patients at each of the three time points, respec-
tively, with median log10 copies/10
6 CD4+ T cells of 0.6 (IQR: 0.7–1.3), 0.5 (IQR: 0.4–0.7) and
0.5 (IQR: 0.4–0.6) at the three time points, respectively.
The long-term (median of 2.5 (IQR: 2.4–2.6) years) and the short-term (median of 31 (IQR:
28–36) days) viral reservoir dynamics of unspliced, multiply spliced HIV-1 RNA, and total
HIV-1 DNA did not significantly differ over time (Fig 2A–2C). Except for 2LTR circles, where
a significant decrease was observed for the long-term reservoir dynamics (Fig 2D).
Fig 1. Workflow schematics.
doi:10.1371/journal.ppat.1005472.g001
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The inter-assay coefficient of variation for total HIV-1 DNA was a median of 13% (IQR:
7–26) for unspliced HIV-1 RNA; the median was 34% (IQR: 27–43) for multiply spliced HIV-
1 RNA, 6% (IQR: 3–12) for total HIV-1 DNA and 26% (IQR: 17–35) for 2LTR circles. Test-
retest variability within patients for quantification of unspliced HIV-1 RNA was a median of
22% (IQR: 17–28) with R2 = 0.92, a median 47% (IQR: 30–83) with R2 = 0.72 for multiply
spliced HIV-1 RNA, a median of 6% (IQR: 6–7) with R2 = 0.99 for total HIV-1 DNA, and a
median of 34% for 2LTR circles (IQR: 16–86) with R2 = 0.95 (S1A–S1D Fig).
HIV-1 reservoir size and its potential for reactivation
Biomarkers for estimating the size of the HIV-1 viral reservoir and its potential to be reacti-
vated included integrated HIV-1 DNA and VOA. Both were assessed at the second time point.
Integrated HIV-1 DNA was detected in all patients with median (IQR) of 3.8 (3.5–4.7) log10
copies/10⁶ CD4+ T cells. Of note, the fact that integrated HIV-1 DNA copies detected by Alu
PCR were higher than total HIV-1 DNA reflects the differences in assay standardization. For
each infected cell, the distance to the nearest Alu element is different. Therefore, a correction
Fig 2. Viral reservoir dynamics. Long and short-term dynamics of cellular markers of HIV-1 persistence. A) unspliced HIV-1 RNA; B) multiply spliced HIV-1
RNA; C) Total HIV-1 DNA; and D) 2LTR circles. *Of note: all analysis was performed using non-parametric statistics.
doi:10.1371/journal.ppat.1005472.g002
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factor is applied based on an integration standard containing proviruses integrated at different
distances from the nearest Alu element. Thus, the Alu PCR is a real-time PCR based assay,
where a standard curve is used that provides a correction factor. Whereas the quantification for
total HIV-1 DNA was performed on digital PCR where no standard curve is used. Hence, the
absolute values for both integrated HIV DNA and total HIV DNA cannot be directly com-
pared. The principle of this assay has been previously described by us and others [17, 18].
Integrated HIV-1 DNA was associated with total HIV-1 DNA (p<0.001, adjusted R² = 0.71,
Spearman’s correlation coefficient R2 = 0.85) (Fig 3A), unspliced HIV-1 RNA (p = 0.029,
adjusted R² = 0.20, Spearman’s correlation coefficient R2 = 0.40) (Fig 3B) and with the viral
outgrowth assay (p = 0.041, adjusted R2 = 0.22, with Spearman’s correlation coefficient R2 =
0.44) (Fig 3C).
Reactivated replication-competent virus was detected in 20/25 (80%) patients by VOA with
a median of 0.52 (IQR: 0.16–0.81) infectious units/10⁶ CD4+ T cells. Total HIV-1 DNA was
associated with IUPM (p = 0.039, adjusted R² = 0.20, Spearman’s correlation coefficient R2 =
0.54) (Fig 3D). Replication-competent HIV-1 was recovered significantly more frequently
from patients with total HIV-1 DNA higher than 3.1 log10 copies/10
6 CD4 + T cells (p = 0.04).
The significant association remained after the removal of the two samples with highest value
for replication-competent virus, assessed by linear correlation analysis (p = 0.011, adjusted
R2 = 0.32, Spearman’s R2 = 0.53) (Fig 3E).
Bland Altman analysis revealed a mean difference (bias) between total HIV-1 DNA and
integrated HIV-1 was median (95% limits of agreement) of -0.57 log10 (0.05 –(-1.19)). The
mean quantification difference between the total HIV-1 DNA or HIV-1 copy numbers quanti-
fied with Alu-PCR (i.e. integrated HIV-1 DNA) and the VOA was 2.23 log10 and 2.88 log10,
respectively. Because of this large difference, we normalized all data to the mean to enable a
comparison by parametric statistics (Fig 4A–4F). The bias between total and integrated HIV-1
DNA was constant (Fig 4E). However, the bias between total or integrated HIV-1 DNA and
the VOA was not constant (Fig 4A and 4C), but it clearly increased linearly with an increasing
average viral reservoir size (Fig 4B and 4D). A regression analysis was performed using the
quantification values of the methods (total and integrated HIV-1 DNA and VOA) to calculate
the intercept and slope (Fig 4B, 4D & 4F). The corresponding intercept and slope for total
HIV-1 DNA and VOA were -0.83 and 1.81 respectively. And the corresponding intercept and
slope for integrated HIV-1 DNA and VOA were -0.77 and 1.53, respectively.
We also performed the Bland Altman analysis between the total HIV-1 DNAmeasurement
from time point 1 and the VOA (median 2.5 years), to assess whether there is also a non-con-
stant quantification bias. Indeed, we observed similar findings (Fig 4G and 4H) compared to
the analysis between total HIV DNA and VOA from the same time point (time point 2) (Fig
4A and 4B).
HIV-1 restriction factor gene expression
Relative mRNA expression of 6 different restriction factors in CD4 T cells was measured at the
second time point. Inverse significant association was found between cell-associated unspliced
HIV-1 RNA and the following restriction factors: TRIM5α (R2 = 0.34, p = 0.003); SAMHD1
(R2 = 0.23, p = 0.031); MX2 (R2 = 0.34, p = 0.035); SLFN11 (R2 = 0.26, p = 0.037) and pSIP1
(R2 = 0.24, p = 0.017) (Fig 5A–5E). APOBEC3G and PAF1 were not correlated with levels of
unspliced HIV-1 RNA, (p = 0.95, p = 0.79), respectively (Fig 5F–5G). In addition, a stepwise
multivariate model was build, which confirmed the inverse significant associations between
unspliced HIV-1 RNA and TRIM5α, SLFN11 and PSIP1 (p = 0.023, p = 0.035, p = 0.044,
respectively).
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Discussion
HIV-1 cure strategies targeting the latent HIV-1 reservoir are increasingly being explored [19].
This emphasizes the need for relevant markers that can be used to monitor the replication
competence of the viral reservoir and to assess efficacy of novel anti-latency strategies. Here,
we performed a comprehensive evaluation of HIV-1 persistence markers in a representative
patient cohort of long-term treated patients who started ART during chronic HIV-1 infection.
We performed a longitudinal analysis of HIV-1 persistence markers measured by ddPCR and
Fig 3. Linear regression analysis between viral reservoir markers. Associations between: A) Integrated HIV-1 DNA and total HIV-1 DNA; B) Integrated
HIV-1 DNA and unspliced HIV-1 RNA; C) Integrated HIV-1 DNA and viral outgrowth assay; D) Total HIV-1 DNA and viral outgrowth assay; and E) Total HIV-1
DNA and viral outgrowth assay–outliers removed.
doi:10.1371/journal.ppat.1005472.g003
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compared to the amount of replication-competent virus measured by VOA. In addition, this
data was correlated with mRNA expression levels of host restriction factors.
In line with earlier reports, our study confirms the long-term stability of HIV-1 DNA levels
in patients followed longitudinally [6, 20]. A stable copy number was observed for the cell-asso-
ciate HIV-1 RNA, as well. A decrease on long-term was observed for only for 2LTR circles.
There have been opposing results published for the half-life of 2LTRs in vivo [21, 22]. Also, it
has been shown that changes in 2LTR circles were not associated with decreases in viral plasma
RNA [23]. In our study, all patients were long-term treated with continuous viral suppression
Fig 4. Bland Altman analysis. Agreement for HIV-1 copies quantification between: A) Total HIV-1 DNA (IDNA) and IUPM, mean difference (log 10) and 95%
Limits of agreement; B) Slope-intercept equation for total HIV-1 DNA and IUPM; C) Integrated HIV-1 DNA (DNA) and IUPM, mean difference (log 10) and
95% Limits of agreement; D) Slope-intercept equation for integrated HIV-1 DNA and IUPM; E) Total HIV-1 DNA (DNA) and integrated HIV-1 DNA (IDNA),
mean difference (log 10) and 95% Limits of agreement; F) Slope-intercept equation for total and integrated HIV-1 DNA; G) Total HIV-1 DNA (DNA)–time point
1 and IUPM–time point 2, mean difference (log 10) and 95% Limits of agreement; and H) Slope-intercept equation for total HIV-1 DNA–time point 1 and
IUPM–time point 2. *Of note: Open label symbol represent test results below the detection threshold for VOA.
doi:10.1371/journal.ppat.1005472.g004
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Fig 5. Linear regression analysis between unspliced (us) HIV-1 RNA and restriction factors. Associations between us HIV-1 RNA and: A) TRIM5α; B)
SAMHD1; C) MX2; D) SLFN11; E) pSIP1; F) APOBEG3G; and G) PAF1.
doi:10.1371/journal.ppat.1005472.g005
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and did not show signs of productive infection during the study conduct. This may result in a
decay of the 2-LTRs, which was observed.
It is well known that this latent reservoir is not eliminated despite continuous ART [24].
Homeostatic proliferation of infected cells and/or residual replication in lymphoid tissue com-
partments may contribute to HIV-1 persistence [25, 26]. The long-lived latent reservoir is
exclusively composed of latent proviral HIV-1 DNA. However, most of the integrated HIV-1
DNA is not replication-competent. Therefore, if the total pool of integrated HIV-1 DNA fails
to correlate with the relatively small replication-competent reservoir then HIV-1 DNAmay
not represent a good biomarker for monitoring viral persistence. In this study, a correlation
was observed between the VOA and the levels of total and integrated HIV-1 DNA. This is the
first study to report these correlations in one patient cohort. A correlation between VOA and
integrated or total HIV-1 DNA was previously observed by Eriksson et al., [12] and Buzon
et al., [16], respectively. This indicates that a stable fraction of integrated HIV-1 is replication-
competent in patients treated during chronic HIV-1 infection. Moreover, we observe similar
mean quantification difference between VOA and total and integrated HIV-1 DNA as was pre-
viously reported by Eriksson et al., (12).
Notably, in this study, Bland Altman analysis revealed a non-constant, but linear quantifica-
tion bias between PCR based methods (for total and integrated HIV-1 DNA) and VOA in
patients (Fig 4A–4F). Thus, indicating that both the total and the integrated HIV-1 DNAmea-
sures can predict the VOA quantification using a prediction formula based on the non-con-
stant difference of the methods [27]. This mutual predictability in HIV-1 quantification
between PCR based and cell culture based methods has not been reported yet and should be
corroborated in further studies. Notably, our study only assessed patients on long-term ART,
treated during chronic HIV infection. Future studies will be required to assess whether anti-
latency drugs affect this correlation, as these treatments may only eliminate the replication-
competent reservoir and may leave the total pool of HIV-1 DNA unchanged.
Interestingly, two recent treatment interruption trials revealed a correlation between inte-
grated ant total HIV-1 DNA levels and time to viral rebound [9, 10]. Moreover, longitudinal
decreases in HIV-1 DNA levels were observed in a substantial part of the functionally cured
patients from the VISCONTI cohort [28]. Although a transient decrease in total HIV DNA,
was recorded in a study where panobinostat was used to reactivate latent HIV-1 reservoir, no
reduction in total HIV DNA, integrated HIV DNA, or infectious units per million cells were
recorded for the whole cohort [29]. Despite, theoretical drawbacks, current clinical data indi-
cate that HIV-1 DNA may still form a valuable biomarker for HIV-1 persistence. Therefore,
PCR based assay quantifying integrated and/or total HIV-1 DNA should still be used in addi-
tion to viral outgrowth assays in future studies aiming at HIV-1 eradication [30, 31].
The measurement of integrated HIV-1 DNA by Alu-PCR [17] is of particular interest
because stable HIV-1 reservoirs in blood have been found to mainly consist of resting CD4+ T
cells harbouring integrated HIV-1 DNA. Although total HIV-1 DNA estimates may be biased
by unintegrated HIV-1 DNA, the correlation observed in our study indicates that total HIV-1
DNA could be a good surrogate maker for integrated HIV-1 DNA in patients on stable ART as
reported earlier [18].
HIV-1 restriction and host factors
In this study a negative significant association was observed between unspliced HIV-1 RNA
and several restriction factors (TRIM5α, MX2, SLFN11, SAMHD1, pSIP1). Only, three of
these findings were confirmed in a multivariate analysis (TRIM5α, SLFN11 and PSIP1). This
result could have been affected from the limited sample size used for this study. TRIM5α is
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known to directly limit HIV-1 production, by inhibiting viral transcription, and other mem-
bers of TRIM family are found to have elevated expression levels in HIV elite controllers [32].
Similarly, in this study, higher expressed levels of TRIM5α were associated with lower
unspliced HIV-1 RNA. SLFN11 exert its HIV-1 antiviral activity indirectly by depleting critical
cellular resources for HIV-1 replication. Additionally, it is an HIV post-integration restriction
factor, which may impede viral production, consistent with our observation between the
expression of SLFN11 and unspliced HIV-1 RNA in patients on stable ART.
A negative association between the expression levels of PSIP1 and unspliced HIV-1 RNA
was observed as well. It is known that PSIP1, which codes for LEDGF/p75 and p52 proteins,
has been implicated in transcriptional regulation and mRNA splicing in vitro, however, its
function in vivo is poorly understood. Recently, was shown that PSIP1 impairs the sites of
HIV-1 integration in the host genome. In this study no association was found between inte-
grated HIV-1 DNA and PSIP1 expression levels.
A significant inverse correlation was found in the univariate analysis between the expression
of MX2 and SAMHD1 with unspliced HIV-1 RNA. MX2 is known to be a key effector of IFNα
mediated HIV-1 resistance [33], and it has been suggested that it destabilizes nuclear forms of
HIV-1 DNA [34]. Recently, it was proposed that MX2 may also interfere with post-nuclear
trafficking and integration [35]. In this study we did observe a negative correlation between
expression on MX2 and unspliced HIV-1 RNA, however, we did not find a significant correla-
tion with the total or integrated HIV-1 DNA. As for SAMHD1, it is proposed that this factor
may also restrict HIV-1 through degradation of viral single stranded RNA and/or DNA [36],
we observed an association with unspliced HIV-1 RNA.
Intriguingly, no correlation was observed between APOBEC3G with any other HIV-1 reser-
voir markers quantified. Association between HIV-1 reservoir markers and differences in
expression levels for APOBEC3G are reported for HIV-1 controllers [37, 38]. The current
study was performed only with non HIV-1 controllers and no correlations with HIV-1 reser-
voir markers were observed. The PAF1 complex has not been fully characterized yet, although
it has been postulated to block HIV replication during the early events from post entry to inte-
gration of proviral DNA into host genome. In this study, we did not observe an association
between PAF1 and the HIV-1 reservoir markers [37].
The expression profile of host restriction factors may play an important role in determining
markers of HIV-1 persistence and their dynamics in patients receiving suppressive therapy.
Therefore, an evaluation of restriction factors with different mechanism of HIV-1 control may
be informative in HIV-1 treatment studies.
Conclusion
Our study reveals important correlations between the VOA and total and integrated HIV-1
DNA. These results show that the total pool of HIV DNA is correlated with the amount of rep-
lication-competent virus. Moreover, the quantification bias between the pool of HIV DNA and
the viral outgrowth assay is functionally dependent, thus, indicating its predictive relevance at
a single patient level. The correlation of HIV-1 RNA transcription and host restriction factors
indicates that host restriction and co factors may be promising additional tools to monitor
patients for functional cure studies.
Materials and Methods
Study population
Eligible patients were HIV-1 positive adult male and female participants from a previous study
conducted at Ghent University Hospital [39]. All participants in the current study were
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receiving stable ART, reporting>95% adherence, and showing a plasma viral load<50 copies/
ml for at least one year. Recruitment occurred at the time of routine visits at Ghent University
Hospital. Patient selection was performed on the basis of baseline (i.e. time point 1) viral reser-
voir measurement (total HIV-1 DNA, cell-associated HIV-1 RNA and 2LTR circles), which
were quantified in a previous study [39]. Three distinct groups of patients were recruited: 1)
Patients with small HIV-1 burden; defined by total HIV-1 DNA—below 100 copies/106
PBMCs, and the CA HIV-1 RNA—below 10 copies/106 PBMCs (N = 10); 2) Patients with high
HIV-1 burden; where the total HIV-1 DNA above 500 copies/106 PBMCs, and the CA HIV-1
RNA is above 20 copies/106 PBMCs (N = 10); and 3) Patients with discordant measures for
total HIV-1 DNA and CA HIV-1 RNA; meaning low number of HIV-1 DNA copies and high
number of CA HIV-1 RNA, and vice versa (N = 5).
Using the clinic’s electronic medical records database, additional information was collected:
age, gender, current and nadir CD4+ T cell count, CD4/CD8 ratio, HIV-1 subtype, pre-ART
plasma viral load zenith, total ART duration, and total duration of plasma viral load suppres-
sion<50 copies/ml. Whole blood was collected in 12 x 9 ml EDTA tubes at time point two,
and additional blood draw of 6 x 9 ml EDTA tubes was taken after median (IQR) of 31 (28–36)
days of the previous blood collection (i.e. time point 3). Fig 1 represents the complete
workflow.
Ethics statement
Ethical approval was obtained from the Ethics Committee of Ghent University Hospital (num-
ber: 2014/0545). All participants provided written informed consent.
Sample preparation for intracellular HIV-1 DNA and HIV-1 RNA
detection
Peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep centrifugation
using (ELITech Group, Benelux), re-suspended in fetal calf serum (FCS) and aliquoted in two
parts of which one was stored at -80°C (to quantify PCR based reservoir markers) and the
other in liquid nitrogen (for the VOA), until further processing. Total HIV-1 DNA, unspliced
and multiply spliced HIV-1 RNA, and 2-LTR circles were quantified in PBMCs using the
QX100 droplet digital PCR system (ddPCR) as previously described [40, 41]. Integrated HIV-1
DNA was quantified in PBMCs using Alu-PCR method as previously described [17].
To measure total HIV-1 DNA, nucleic acid was extracted from 5–10 x 106 PBMCs using the
DNeasy mini kit (Qiagen, Venlo, The Netherlands) with an elution buffer preheated at 56°C
for 5 min. The isolated DNA was subjected to restriction digest by Promega EcoRI (Promega,
Madison, Wisconsin) to ensure a uniform DNA distribution in the ddPCR droplets. Each
restriction digest contained median of 2.8 μg (IQR 2.3–3.9) of DNA in a total volume of 16 μl,
which was incubated at room temperature for 2h prior to the ddPCR assay.
To measure HIV-1 RNA, nucleic acid was extracted from 10–20 x 106 PBMCs using the
RNeasy mini kit (Qiagen), eluted in 30 μl nuclease-free water (Qiagen), and subjected to
DNase treatment on column with the RNase free DNase kit (Qiagen). Total of 2 μg RNA was
reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad) and the cDNA was used to
measure unspliced and multiply spliced HIV-1 RNA in the ddPCR assay.
To measure 2-LTR circles, nucleic acid was extracted from 5–10 x 106 PBMCs using the
QIAprep Spin Miniprep kit (Qiagen). Prior to extraction, samples were spiked with known
copy numbers of the pSIF1-H1-Puro non-HIV plasmid (System Biosciences, Mountain view,
California) as an internal control for normalization to cell equivalents per sample as described
previously [40].
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Droplet digital PCR (ddPCR)
The ddPCR assays for measuring total HIV-1 DNA, unspliced and multiply spliced HIV-1
RNA, and 2-LTR circles were performed as reported previously using the described primer and
probe sets, all primer pairs sequencing are provided in S1 Table. The ddPCR reaction mix con-
sisted of 10 μl 2x ddPCR super mix for probes (Bio-Rad), 500 nM primers, 250 nM probe, and
4 μl of cDNA for HIV-1 RNA; 4 μl of restriction digest for HIV-1 DNA; or 4 μl of sample for
2-LTR circles, into a final volume of 20 μl. All samples were tested in triplicate; the reference
gene—RPP30, was tested in duplicate. No-template controls (NTCs) with water and cDNA or
DNA from non-infected PBMCs were included in every run. Results are reported as copies/106
PBMCs, and for the changes in of the reservoir markers we have normalized to percentages of
CD4 T cells. Inter assay coefficient of assay variation (CV) and test-retest CV (i.e. intra patient
variation) were calculated for all ddPCR assays.
Alu PCR (Integrated HIV-1 DNA)
Alu-HIV PCR was performed as described earlier by De Spiegelaere et al., [17] using 42 repli-
cate reactions of a mix with gag-reverse HIV primer and Alu-forward primer as well as 42 rep-
licates by use of only primers specific to HIV gag (HIV-only PCR). Samples were diluted to 2
or 10 μg DNA/mL and distributed in replicate PCR reactions containing 25 μL sample com-
bined with 25 μL master mix, resulting in an equivalent of approximately 7500 cells (1 ng/μL
PCR mix) or approximately 37 500 cells (5 ng/μL PCR mix) per 50 μL PCR replicate. All
patient samples were run at 7500 cells/replicate PCR. We conducted the final nested qPCR in
20 μL with 10 μL of the first PCR product. This qPCR was optimized to enable robust amplifi-
cation in a 1:1 dilution of PCR without PCR inhibition from pyrophosphates. We used master
mixes and cycling conditions as previously described [42], and primer pairs are depicted in S1
Table. PCR cycling was performed on a Roche Real-Time PCR System (Light Cycler 480), and
Cq values were obtained by second derivative analysis.
Reference gene normalization for intracellular HIV-1 RNA quantification
To minimise assay variability, ddPCR results for the unspliced and multiply spliced HIV-1
RNA expression were normalized using internal reference genes [43, 44]. A set of eight refer-
ence genes was first ranked based on expression stability using the geNorm method in qBase
Plus (Biogazelle, Ghent, Belgium) using real time quantitative PCR (qPCR) as previously
described [45]. The geometric mean of the two most stably expressed reference genes (B2M
and YWHAZ) was used to calculate the normalization factor of each clinical specimen [46].
Subsequently, raw ddPCR values for unspliced and multiply spliced HIV-1 RNA were normal-
ized and reported as copies/106 PBMCs for each patient, and for the changes in of the reservoir
markers are normalized to percentages of CD4 T cells.
mRNA expression of host/restriction factors
In all patient samples, mRNA levels of 7 restriction factors were assessed by quantitative
reverse transcription PCR (RT-qPCR). TRIM5α, SAMHD1, APOBEC3G, MX2, PAF1,
SLFN11, and pSIP1 were selected from previously published studies [32, 37]. The restriction
factors were quantified by use of predesigned PrimePCR Sybrgreen Assays, from Bio-Rad (Bio-
Rad, Hercules, California) with following unique assay IDs: 0010567, 0042858, 0048756,
0014994, 0003366, 0034707, and 00367525, respectively. qPCR concentration mix and cycling
conditions were used as recommended by the manufacturer on a Roche Real-Time PCR System
HIV-1 Reservoir Size and Dynamics in Patients on ART
PLOS Pathogens | DOI:10.1371/journal.ppat.1005472 March 3, 2016 13 / 17
(Light Cycler 480). The raw qPCR data for the restriction factors were normalized with the 2
most stable reference genes as indicated for the HIV-1 quantification.
Viral outgrowth assay (VOA)
Viral outgrowth assays were performed as previously described [16]. PBMC samples were
shipped on dry ice to the Ragon institute (Cambridge, MA, US), total pool of CD4+ T cells
were isolated from 100–150 million PBMCs and seeded at 20–50,000 cells/well in round-bot-
tom 96-well plates. CD4+ T cells were stimulated with PHA (2μg/ml), rh IL-2 (100 units/ml)
and co-cultured with irradiated allogeneic PBMCs from HIV negative healthy donors. At day 2
and day 9 of culture MOLT4/CCR5 cells were added to each well to enhance the survival of the
cultured primary isolated cells and to support and facilitate further HIV-1 replication. Culture
medium containing rh IL-2 (NIH AIDS reagents program) was replaced at days 2 and 6 of cul-
ture. After 12 days of culture, the cell supernatant from each well was harvested and incubated
for 48h with TZM-bl cells (NIH AIDS reagents program), a permissive HeLa cell clone that
contains HIV-1 Tat-responsive reporter genes for firefly luciferase under control of the HIV-1
LTR, permitting sensitive and accurate measurements of HIV-1 infection [16]. Luciferase activ-
ity was quantified by luminescence that is directly proportional to the number of infectious
virus particles present in the initial inoculum. Estimated frequencies of cells with replication-
competent HIV-1 were calculated using limiting dilution analysis, using http://bioinf.wehi.edu.
au/software/elda/, as previously described [16].
Statistical analysis
Baseline patient characteristics were described using either frequency for categorical variables
or median [interquartile range (IQR)] for continuous variables. Differences between time
points for the viral reservoir markers were assessed by standard non-parametric tests; Mann-
Whitney and Kruskal-Wallis tests were used when appropriate. Linear regression and Spear-
man’s correlation were performed to assess relationships between different HIV reservoir vari-
ables. We report the adjusted R2 from the linear regression and the correlation coefficient as
well. Linear regression analysis was performed to assess relationship between unspliced HIV-1
RNA and several HIV restriction and host factors, individually. In addition, a multivariate lin-
ear stepwise model was build. Bland Altman tests were used to assess the quantitative agree-
ment between Alu-PCR (integrated HIV-1 DNA), the viral outgrowth assay (VOA) and total
HIV-1 DNA (ddPCR) for HIV-1 copy measurements in patient samples. For all tests used, the
level of significance accepted was p<0.05. Statistical analyses were performed using R, packages
used MethComp and JAGS 3.4.0.
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